![]() | |
![]() Former headquarters in Sunnyvale, California | |
Company type | Public |
---|---|
OTC Pink: MEHCQ Nasdaq: ME | |
ISIN | US90138Q3065 US90138Q4055 ![]() |
Industry | |
Founded | April 2006 |
Founders |
|
Fate | Filed for Chapter 11 bankruptcy in March 2025 |
Headquarters | , United States |
Key people |
|
Products | |
Services | |
Revenue | ![]() |
![]() | |
![]() | |
Total assets | ![]() |
Total equity | ![]() |
Number of employees | 582 (2024) |
Website | 23andme |
Footnotes / references Financials as of March 31, 2024[update].[1] |
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California.[1] It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping,[2] to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.[3]
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use.[4] Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.[5][6]
The company had a previously fraught relationship with the United States Food and Drug Administration (FDA) due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval.[7][8] 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014,[9][10][11] and in the UK since December 2014.[12]
23andMe became a publicly traded company in 2021, via a merger with a Special Purpose Acquisition Company (SPAC), and soon had a market capitalization of US$6 billion.[13] By 2024, its valuation had fallen to 2% of that peak.[13] In March 2025, 23andMe filed for Chapter 11 bankruptcy, and CEO Anne Wojcicki resigned.[14] Due to the sensitive nature of data stored by 23andMe and privacy concerns due to bankruptcy filing,[15] the attorney general of California subsequently issued a consumer alert for its customers.[16]
On May 19, 2025, Regeneron agreed to buy 23andMe out of bankruptcy for $256 million.[17] In June 2025, TTAM Research Institute, a non-profit founded by Anne Wojcicki, outbid Regeneron and won the bid for 23andMe for $305 million.[18]
Wired2007
was invoked but never defined (see the help page).
Time
was invoked but never defined (see the help page).
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search